|
?:authorAffiliation
|
-
[\'From the Novartis Pharmaceuticals Corporation (R.S.), East Hanover, NJ; Novartis Pharma AG (A.K., T.H., V.D.), Basel, Switzerland; Department of Neurology, Technical University of Munich, and Munich Cluster for Systems Neurology (SyNergy) (B.H.), Germany; Weill Institute for Neurosciences (B.A.C.C.), Department of Neurology, University of California San Francisco, CA; Department of Neurology (B.M.G.), University of Texas Southwestern, Dallas, TX; Novartis Healthcare Pvt. Ltd. (U.K.), Hyderabad, India; Department of Medicine (B.J.W.), Division of Experimental Medicine, Research Institute of the McGill University Health Centre, Montreal, Canada; and Department of Neurology (J.B.), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. roseanne.sullivan@novartis.com.\', \'From the Novartis Pharmaceuticals Corporation (R.S.), East Hanover, NJ; Novartis Pharma AG (A.K., T.H., V.D.), Basel, Switzerland; Department of Neurology, Technical University of Munich, and Munich Cluster for Systems Neurology (SyNergy) (B.H.), Germany; Weill Institute for Neurosciences (B.A.C.C.), Department of Neurology, University of California San Francisco, CA; Department of Neurology (B.M.G.), University of Texas Southwestern, Dallas, TX; Novartis Healthcare Pvt. Ltd. (U.K.), Hyderabad, India; Department of Medicine (B.J.W.), Division of Experimental Medicine, Research Institute of the McGill University Health Centre, Montreal, Canada; and Department of Neurology (J.B.), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}